DeepMed Research

Isosorbide

Generic Name: Isosorbide

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₀O_₄

CAS Number: 652-67-5

Unique Ingredient Identifier: WXR179L51S

Background: Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. Currently, isosorbide is an organic nitrate currently available in the isosorbide mononitrate and isosorbide dinitrate forms, and is used for the prevention of angina. Refer to these drug entries for more information.

Indication: Isosorbide was previously indicated for temporary reduction of intraocular pressure and used to interrupt an acute glaucoma attack, however, this is not a currently approved indication. Refer to isosorbide mononitrate and isosorbide dinitrate drug entries for more isosorbide indications.

Associated Conditions: Angina Pectoris

Clinical Trials

Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization

Phase 4

Conditions: Coronary Artery Disease(CAD)

Interventions: Drug: DanLou Tablet placebo
Drug: Danlou Tablet
Drug: Aspirin Enteric-coated Tablets
Drug: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Drug: Atorvastatin calcium
Drug: Isosorbide Mononitrate Tab 20 MG
Drug: Metoprolol Tartrate Tab 25 MG
Drug: Trimetazidine Dihydrochloride Tablets

First Posted Date: 2017-03-07

Last Posted Date: 2017-04-04

Lead Sponsor: Jun Li

Target Recruit Count: 440

Registration Number: NCT03072082

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Phase 4

Conditions: Coronary Artery Disease(CAD)

Interventions: Drug: Shexiang Baoxin pill
Drug: SBP placebo
Drug: Aspirin Enteric-coated Tablets
Drug: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Drug: Atorvastatin Calcium
Drug: Isosorbide Mononitrate Tab 20 MG
Drug: Metoprolol Tartrate Tab 25 MG
Drug: Trimetazidine Dihydrochloride Tablets

First Posted Date: 2017-03-07

Last Posted Date: 2017-04-04

Lead Sponsor: Jun Li

Target Recruit Count: 440

Registration Number: NCT03072121

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

Phase 4

Completed

Conditions: Insulin Resistance Syndrome
Atherosclerosis, Coronary
Adverse Effect

Interventions: Drug: Isosorbide Dinitrate 10Mg Tablet
Drug: Pioglitazone 15 mg Tablet
Drug: Acetylsalicylic Acid 75Mg Tablet
Drug: Rosuvastatin Calcium 20 MG Oral Tablet
Drug: Bisoprolol Fumarate 2.5 MG Oral Tablet
Drug: Ramipril 5 MG

First Posted Date: 2017-01-05

Last Posted Date: 2022-03-10

Lead Sponsor: Ukrainian Medical Stomatological Academy

Target Recruit Count: 43

Registration Number: NCT03011775

Locations: 🇺🇦
Ukrainian Medical Stomatological Academy, Poltava, Ukraine

Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets

Phase 4

Completed

Conditions: Meniere's Disease

Interventions: Drug: Meniace
Drug: Isobide

First Posted Date: 2016-03-24

Last Posted Date: 2016-03-24

Lead Sponsor: Alvogen Korea

Target Recruit Count: 220

Registration Number: NCT02718846

Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.

Not Applicable

Completed

Conditions: Coronaropathy

Interventions: Drug: dinitrate isosorbide
Drug: nitroglycerine

First Posted Date: 2014-10-07

Last Posted Date: 2014-10-07

Lead Sponsor: Brugmann University Hospital

Target Recruit Count: 442

Registration Number: NCT02258620

Locations: 🇧🇪
CHU-Brugmann, Bruxelles, Belgium

Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function

Phase 2

Withdrawn

Conditions: Hypertension

Interventions: Drug: Isosorbide Mononitrate, sustained release
Drug: Placebo capsule

First Posted Date: 2013-10-11

Last Posted Date: 2016-08-11

Lead Sponsor: Corporal Michael J. Crescenz VA Medical Center

Registration Number: NCT01961453

Locations: 🇺🇸
Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Isosorbide dinitrate / hydralazine capsules

First Posted Date: 2012-04-30

Last Posted Date: 2015-08-06

Lead Sponsor: Arbor Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT01587313

Locations: 🇺🇸
Frontage Cinical Services, Hackensack, New Jersey, United States

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

Phase 2

Completed

Conditions: Congestive Heart Failure
Heart Failure

Interventions: Drug: Placebo
Drug: Isosorbide Dinitrate + Hydralazine
Drug: Isosorbide Dinitrate

First Posted Date: 2012-01-24

Last Posted Date: 2022-06-21

Lead Sponsor: Corporal Michael J. Crescenz VA Medical Center

Target Recruit Count: 44

Registration Number: NCT01516346

Locations: 🇺🇸
Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States

A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis

Phase 4

Completed

Conditions: Coronary Artery Stenosis
Coronary Heart Disease

Interventions: Drug: Quick-Acting Heart Reliever
Drug: Isosorbide Dinitrate
Drug: Placebo of Isosorbide Dinitrate
Drug: Placebo of Quick-Acting Heart Reliever
Drug: Aspirin Enteric-coated Tablets

First Posted Date: 2012-01-20

Last Posted Date: 2014-08-05

Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 120

Registration Number: NCT01513070

Locations: 🇨🇳
Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: losartan potassium

First Posted Date: 2009-07-22

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 13

Registration Number: NCT00943852

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy